Project Grant R01HL180833
Award Date 9/1/25
Completion Date 6/30/30
Dollars Obligated $763K
Federal Agency
Federal Grant Program
Assistance Type
Project Grant
Place of Performance
Worcester, MA 01655, USA
Similar Awards
- The National Heart, Lung, and Blood Institute (NHLBI) has awarded a $126,309 Project Grant under the Cardiovascular Diseases Research program (CFDA 93.837) to Children's Hospital Medical Center in Cincinnati, Ohio. This 2-year research project, awarded on June 16, 2025, aims to characterize the functional role of a novel cardiac and adipose-enriched microprotein called NRAC and its involvement in lipid droplet biogenesis and lipid metabolism within the cardiovascular system. The research will...
- The National Heart, Lung, and Blood Institute (NHLBI), part of the National Institutes of Health, awarded a $1,127,798 Project Grant under the Cardiovascular Diseases Research program (CFDA 93.837) to The General Hospital Corporation, doing business as Massachusetts General Hospital (MGH). This 7-year grant, effective February 1, 2025, will support research to understand the role of macrophages in preserving cardiovascular health, illuminating their contributions to cardiovascular disease, and...
- The National Heart, Lung, and Blood Institute (NHLBI), part of the National Institutes of Health (NIH), awarded a $766,920 Project Grant under the Cardiovascular Diseases Research (CFDA 93.837) program. The grant, effective May 15, 2025 through February 28, 2029, will support research by Augusta University Research Institute, Inc. (doing business as Georgia Health Sciences) to investigate the mechanisms linking skeletal muscle health and vascular function in obesity. The research aims to...
- The National Heart, Lung, and Blood Institute (NHLBI), under CFDA Program 93.837 Cardiovascular Diseases Research, awarded a $802,611 Project Grant to the Rector & Visitors of the University of Virginia (UVA) with a performance period from September 15, 2025 to August 31, 2029. The purpose of this grant is to develop improved cardiac MRI (CMR) methods to quantify epicardial adipose tissue (EAT) composition and demonstrate the advantages of EAT composition imaging in advancing the...
- The National Heart, Lung, and Blood Institute (NHLBI) awarded a $705,279 Project Grant (CFDA 93.837 - Cardiovascular Diseases Research) to Trustees of Boston University, doing business as Boston University Medical Campus, to investigate the mechanisms by which environmental pollutants impact the cardiovascular system. The 4-year project, starting January 1, 2025, will use a multidisciplinary approach including physiological studies, cellular imaging, RNA-sequencing, and mouse models to...
- The National Heart, Lung, and Blood Institute (NHLBI) awarded a $245,626 Project Grant under the Cardiovascular Diseases Research program (CFDA 93.837) to The Johns Hopkins University. The grant, with a project period from February 1, 2025 to January 31, 2027, will fund research to validate lipidomic signatures associated with right ventricular and pulmonary vascular dysfunction in pulmonary arterial hypertension (PAH). The project aims to replicate the researchers' preliminary findings on...
- This $787,453 federal Project Grant awarded by the National Heart, Lung, and Blood Institute (CFDA 93.837 Cardiovascular Diseases Research) to Brigham & Women's Hospital Inc. aims to develop a new lipid-lowering and anti-inflammatory siRNA therapy for more effective treatment of atherosclerotic cardiovascular disease (ASCVD). The project will leverage the researchers' recent discoveries on the biological roles of epsin endocytic adaptor proteins in regulating lipid metabolism and arterial...
- The National Heart, Lung, and Blood Institute (NHLBI) has awarded a $2,442,173 Project Grant under the Cardiovascular Diseases Research program (CFDA 93.837) to The Leland Stanford Junior University (Stanford University) to identify genes and pathways that influence the risk of vascular diseases such as coronary artery disease (CAD) and pulmonary arterial hypertension (PAH). The 5-year award, effective August 15, 2025, will leverage innovative CRISPR genomics approaches to characterize gene...
- This $713,382 Project Grant award from the National Heart Lung and Blood Institute's Cardiovascular Diseases Research program (CFDA 93.837) supports research at the University of Pennsylvania on the role of triglyceride-rich lipoproteins in the growth and progression of abdominal aortic aneurysms. The research aims to generate definitive causal evidence on how triglyceride-rich lipoproteins influence the development, growth, and rupture of these life-threatening aortic aneurysms, with the goal...
- This $559,893 Project Grant award from the National Heart Lung and Blood Institute under the Cardiovascular Diseases Research program (CFDA 93.837) supports research to investigate the role of RSPO2 signaling through the LGR4 receptor in regulating arterial lymphangiogenesis, vascular smooth muscle cell phenotype, and atherosclerosis development. The project will be conducted by the University of Tennessee Health Science Center in Memphis, Tennessee over a 5-year period from January 2025 to...